1. An antimicrobial peptide, wherein the peptide has a length of from about 10 amino acids to about 50 amino acids, and wherein the peptide comprises an amino acid sequence having at least about 90% amino acid sequence identity to a contiguous stretch of from about 10 amino acids to about 35 amino acids of the sequence
(SEQ\u2003ID\u2003NO:\u200363)
YSYGSGLGVGGGFSSSSGRAIGGGLSSVGGGSSTIKYTTTSSSSR.
2. The antimicrobial peptide of claim 1, wherein the peptide comprises an amino acid sequence selected from:
(SEQ\u2003ID\u2003NO:\u20031)
AIGGGLSSVGGGSSTIK;
(SEQ\u2003ID\u2003NO:\u20032)
AIGGGLSSVGGGSSTIKY;
(SEQ\u2003ID\u2003NO:\u20033)
RAIGGGLSSVGGGSSTIK;
(SEQ\u2003ID\u2003NO:\u20034)
GGLSSVGGGSSTIK;
(SEQ\u2003ID\u2003NO:\u20035)
AIGGGLSSVGGGS;
(SEQ\u2003ID\u2003NO:\u20036)
RAIGGGLSSVGGGSSTIKY;
(SEQ\u2003ID\u2003NO:\u20037)
YGSGLGVGGGFSSSSGRAIGGGLSSVGGGSSTIKY;
(SEQ\u2003ID\u2003NO:\u20038)
YGSGLGVGGGFSSSSGRAIGGGLSSVGGGSSTIKYT;
and
(SEQ\u2003ID\u2003NO:\u20039)
GGLSSVGGGS.
3. The antimicrobial peptide of claim 1, wherein at least two adjacent amino acids are joined via a linkage other than an amide bond.
4. An antimicrobial peptide of claim 1, wherein the peptide comprises at least one phosphorylated tyrosine residue.
5. A composition comprising the antimicrobial peptide of claim 1.
6. The composition of claim 4, wherein the composition is a disinfectant.
7. The composition of claim 6, further comprising one or more of a surfactant, a pH adjusting agent, a dye, a fragrance, and a complexing agent.
8. The composition of claim 4, wherein the composition is a solid, a liquid, or a gel.
9. A pharmaceutical formulation comprising:
a) the antimicrobial peptide of claim 1; and
b) a pharmaceutically acceptable excipient.
10. A wound or surgical dressing comprising:
i) a substrate;
ii) and an antimicrobial peptide of claim 1 bound to the substrate.
11. The wound or surgical dressing of claim 10, wherein the substrate comprises a gauze; an elastic material; a coform web; an airlaid web; a bonded carded web; a wetlaid web; a foam; a film; a woven fabric; a knitted fabric; or a hydroentangled web.
12. The wound or surgical dressing of claim 10, wherein the wound or surgical dressing comprises an adhesive bandage or a wrapping.
13. A method of inhibiting growth of a bacterium, the method comprising contacting the bacterium with a growth inhibiting amount of the antimicrobial peptide of claim 1.
14. The method of claim 13, wherein said contacting is carried out in vitro.
15. The method of claim 14, wherein the bacterium is on the surface of a medical device.
16. The method of claim 14, wherein the bacterium is on a hard surface in a healthcare facility, an educational facility, a detention facility, or a residence.
17. The method of claim 13, wherein the bacterium is in a liquid.
18. The method of claim 13, wherein said contacting is in vivo.
19. A method of treating a bacterial infection in an individual, the method comprising administering to the individual an effective amount of the peptide of claim 1.
20. An implantable or insertable medical device comprising the peptide of claim 1.
21. The implantable or insertable medical device of claim 20, wherein the implantable or insertable medical device is a contact lens.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by the following formula I:
(wherein the cyclic amino group is represented by the following formula II:
in which the cyclic amino group is a 3- to 8-membered saturated cyclic amine or a 3- to 8-membered saturated cyclic amine bridged with C1-5alkylene or C1-4alkylene-O-C1-4alkylene between any different two carbon atoms of the cyclic amine, which cyclic amine is substituted with a group represented by \u2014(CR1R2)m\u2014(CHR3)n\u2014X, R4 and R5 independently on the same or different carbon atoms of the cyclic amine;
X is cyano, hydroxy or \u2014OR9;
Y is N or CR10;
R1 is hydrogen, hydroxy, C1-5alkyl, C1-5alkoxy-C1-5alkyl or hydroxy-C1-5alkyl;
R2 is hydrogen or C1-5alkyl;
R3 is hydrogen, cyano, C1-5alkyl, C1-5alkoxy-C1-5alkyl or hydroxy-C1-5alkyl;
m is an integer selected from 0, 1, 2, 3, 4 and 5;
n is 0 or 1;
with the proviso that when X is hydroxy or OR9, and n is 0, then m is an integer selected from 1, 2, 3, 4 and 5;
R4 is hydrogen, hydroxy, hydroxy-C1-5alkyl, cyano, cyano-C1-5alkyl or C1-5alkyl;
R5 is hydrogen or C1-5alkyl;
R6 is hydrogen, C1-5alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-5alkyl, hydroxy, C1-5alkoxy, C3-8cycloalkyloxy or \u2014N(R11)R12;
R7 and R8 are the same or different, and independently are hydrogen, halogen, C1-5alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-5alkyl, hydroxy, C1-5alkoxy, C3-8cycloalkyloxy, \u2014N(R11a)R12a, \u2014CO2R13, cyano, nitro, C1-5alkylthio, trifluoromethyl or trifluoromethoxy; or R7 and R8 are taken together to form \u2014CH2\u2014CH2\u2014CH2\u2014CH2\u2014 or \u2014CH\u2550CH\u2014CH\u2550CH\u2014;
R9 is C1-24acyl, C1-10alkoxycarbonyl, aryl-C1-5alkyloxycarbonyl, \u2014CO\u2014O\u2014CHR14\u2014O\u2014CO\u2014R15, \u2014P(\u2550O)(OR14a)OR15a, \u2014CO\u2014(CH2)p\u2014(CHR16)q\u2014NR17R18, arylcarbonyl or heteroarylcarbonyl, wherein each said acyl, aryl and heteroaryl is unsubstituted or substituted with C1-5alkoxy, and C1-24acyl optionally includes one to six double bonds;
R10 is hydrogen, C1-5alkyl, halogen, cyano or \u2014CO2R19;
Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C1-5alkyl, C3-8cycloalkyl, C2-5alkenyl, C2-5alkynyl, C1-5alkoxy, C1-5alkylthio, C1-5alkylsulfinyl, C1-5alkylsulfonyl, cyano, nitro, hydroxy, \u2014CO2R19a, \u2014C(\u2550O)R19a, \u2014CONR11bR12b, \u2014OC(\u2550O)R19a, \u2014NR11bCO2R19a, \u2014S(O)rNR11bR12b, hydroxy-C2-5alkylamino-C2-5alkoxy, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy, methylenedioxy, ethylenedioxy and \u2014N(R20)R21; with the proviso that when X is hydroxy, Y is N, and the cyclic amino group is 5-membered ring, then Ar is aryl or heteroaryl which aryl or heteroaryl is substituted with at least one of substituents which are selected from halogen and trifluoromethyl;
R11 and R12 are the same or different, and independently are hydrogen, C1-5alkyl, C3-8cycloalkyl or C3-8cycloalkyl-C1-5alkyl;
R11a and R12a are the same or different, and independently are hydrogen, C1-5alkyl, C3-8cycloalkyl or C3-8cycloalkyl-C1-5alkyl;
R11b and R12b are the same or different, and independently are hydrogen, C1-5alkyl, C3-8cycloalkyl or C3-8cycloalkyl-C1-5alkyl;
R13 is hydrogen, C1-5alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-5alkyl, C1-5alkoxy-C1-5alkyl, C3-8cycloalkyloxy-C1-5alkyl or phenyl;
R14 and R15 are the same or different, and independently are hydrogen, C1-5alkyl or aryl-C1-5alkyl;
R14a a and R15a are the same or different, and independently are hydrogen, C1-5alkyl or aryl-C1-5alkyl;
R16 is hydrogen, C1-5alkyl, aryl, heteroaryl, aryl-C1-5alkyl, heteroaryl-C1-5alkyl, hydroxy-C1-5alkyl, hydroxycarbonyl-C1-5alkyl, hydroxyphenyl-C1-5alkyl, C1-5alkoxy-C1-5alkyl, amino-C1-5alkyl, guanidino-C1-5alkyl, mercapto-C1-5alkyl, C1-5alkylthio-C1-5alkyl or aminocarbonyl-C1-5alkyl;
R17 and R18 are the same or different, and independently are hydrogen, C1-5alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-5alkyl, C1-10acyl, C1-10alkoxycarbonyl or aryl-C1-5alkyloxycarbonyl;
or R16 and R17 are taken together to form \u2014CH2-, \u2014CH2CH2\u2014, \u2014CH2CH2CH2\u2014 or \u2014CH2CH2CH2CH2\u2014;
p is an integer selected from 0, 1, 2, 3, 4 and 5;
q is 0 or 1;
R19 is hydrogen or C1-5alkyl;
R19a is hydrogen or C1-5alkyl;
r is 1 or 2;
R20 and R21 are the same or different, and independently are hydrogen or C1-5alkyl), individual isomers thereof, racemic or non-racemic mixtures of isomers thereof or N-oxide thereof, or pharmaceutically acceptable salts and hydrates thereof.
2. The pyrrolopyrimidine or pyrrolopyridine derivative substituted with the cyclic amino group according to claim 1, which is a compound represented by the following formula III:
(wherein the cyclic amino group is represented by the following formula IV:
in which the cyclic amino group is a 3- to 8-membered saturated cyclic amine or a 3- to 8-membered saturated cyclic amine bridged with C1-5alkylene or C1-4alkylene-O-C1-4alkylene between any different two carbon atoms of the cyclic amine, which cyclic amine is substituted with a group represented by \u2014(CR1R2)m\u2014(CHR3)n\u2014CN, R4 and R5 independently on the same or different carbon atoms of the cyclic amine;
Y is N or CR10;
R1 is hydrogen, hydroxy, C1-5alkyl, C1-5alkoxy-C1-5alkyl or hydroxy-C1-5alkyl;
R2 is hydrogen or C1-5alkyl;
R3 is hydrogen, cyano, C1-5alkyl, C1-5alkoxy-C1-5alkyl or hydroxy-C1-5alkyl;
m is an integer selected from 0, 1, 2, 3, 4 and 5;
n is 0 or 1;
R4 is hydrogen, hydroxy, hydroxy-C1-5alkyl, cyano, cyano-C1-5alkyl or C1-5alkyl;
R5 is hydrogen or C1-5alkyl;
R6 is hydrogen, C1-5alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-5alkyl, hydroxy, C1-5alkoxy, C3-8cycloalkyloxy or \u2014N(R11)R12;
R7 and R8 are the same or different, and independently are hydrogen, halogen, C1-5alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-5alkyl, hydroxy, C1-5alkoxy, C3-8cycloalkyloxy, \u2014N(R11a)R12a, \u2014CO2R12a, cyano, nitro, C1-5alkylthio, trifluoromethyl or trifluoromethoxy; or R7 and R8 are taken together to form \u2014CH2\u2014CH2\u2014CH2\u2014CH2\u2014 or \u2014CH\u2550CH\u2014CH\u2550CH\u2014;
R10 is hydrogen, C1-5alkyl, halogen, cyano or \u2014CO2R19;
Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C1-5alkyl, C3-8cycloalkyl, C2-5alkenyl, C2-5alkynyl, C1-5alkoxy, C1-5alkylthio, C1-5alkylsulfinyl C1-5alkylsulfonyl, cyano, nitro, hydroxy, \u2014CO2R19a, \u2014C(\u2550O)R19a, \u2014CONR11bR12b, \u2014OC(\u2550O)R19a, \u2014NR11bCO2R19a, \u2014S(O)rNR11R12b, hydroxy-C2-5alkylamino-C2-5alkoxy, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy, methylenedioxy, ethylenedioxy and \u2014N(R20)R21;
R11 and R12 are the same or different, and independently are hydrogen, C1-5alkyl, C3-8cycloalkyl or C3-8cycloalkyl-C1-5alkyl;
R11a and R12a are the same or different, and independently are hydrogen, C1-5alkyl, C3-8cycloalkyl or C3-8cycloalkyl-C1-5alkyl;
R11b and R12b are the same or different, and independently are hydrogen, C1-5alkyl, C3-8cycloalkyl or C3-8cycloalkyl-C1-5alkyl;
R13 is hydrogen, C1-5alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-5alkyl, C1-5alkoxy-C1-5alkyl, C3-8cycloalkyloxy-C1-5alkyl or phenyl;
R19 is hydrogen or C1-5alkyl;
R19a is hydrogen or C1-5alkyl;
r is 1 or 2;
R20 and R21 are the same or different, and independently are hydrogen or C1-5alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof
3. The pyrrolopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula III, wherein Y is N; the cyclic amino group, m, n, R1, R2, R3, R4, R5, R6, R7, R8 and Ar are as defined in claim 2; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
4. The pyrrolopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula III, wherein Y is N; n is 0; R1, R2, R4 and R5 are hydrogen; the cyclic amino group, m, R6, R7, R8 and Ar are as defined in claim 2; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
5. The pyrrolopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula III, wherein Y is N; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; m is an integer selected from 0, 1, 2 and 3; n is 0; R1, R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or C1-5alkyl; Ar is phenyl or pyridyl which phenyl or pyridyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and \u2014N(R20)R21 (wherein R20 and R21 are the same or different, and independently are hydrogen or C1-3alkyl); individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
6. The pyrrolopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula III, wherein Y is N; the cyclic amino group is a 6-membered saturated cyclic amine; m is 0 or 1; n is 0; R1, R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or methyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of chloro, bromo, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and dimethylamino; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
7. The pyrrolopyridine derivative substituted with the cyclic amino group according to claim 2 represented by formula III, wherein Y is CR10; the cyclic amino group, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R10 and Ar are as defined in claim 2; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
8. The pyrrolopyridine derivative substituted with the cyclic amino group according to claim 2 represented by formula III, wherein Y is CR10; n is 0; R1, R2, R4 and R5 are hydrogen; R10 is hydrogen or halogen; the cyclic amino group, m, R6, R7, R8 and Ar are as defined in claim 2; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
9. The pyrrolopyridine derivative substituted with the cyclic amino group according to claim 2 represented by formula III, wherein Y is CR10; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; m is an integer selected from 0, 1, 2 and 3; n is 0; R1, R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or C1-5alkyl; R10 is hydrogen or halogen; Ar is phenyl or pyridyl which phenyl or pyridyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and \u2014N(R20)R21 (wherein R20 and R21 are the same or different, and independently are hydrogen or C1-3alkyl); individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
10. The pyrrolopyridine derivative substituted with the cyclic amino group according to claim 2 represented by formula III, wherein Y is CR10; the cyclic amino group is a 6-membered saturated cyclic amine; m is 0 or 1; n is 0; R1, R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or methyl; R10 is hydrogen; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of chloro, bromo, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and dimethylamino; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
11. The pyrrolopyrimidine or pyrrolopyridine derivative substituted with the cyclic amino group according to claim 1, which is a compound represented by the following formula V:
(wherein the cyclic amino group is represented by the following formula VI:
in which the cyclic amino group is a 3- to 8-membered saturated cyclic amine or a 3- to 8-membered saturated cyclic amine bridged with C1-5alkylene or C1-4alkylene-O-C1-4alkylene between any different two carbon atoms of the cyclic amine, which cyclic amine is substituted with a group represented by \u2014(CR1R2)m\u2014(CHR3)n\u2014OH, R4 and R5 independently on the same or different carbon atoms of the cyclic amine;
Y is N or CR10;
R1 is hydrogen, hydroxy, C1-5alkyl, C1-5alkoxy-C1-5alkyl or hydroxy-C1-5alkyl;
R2 is hydrogen or C1-5alkyl;
R3 is hydrogen, cyano, C1-5alkyl, C1-5alkoxy-C1-5alkyl or hydroxy-C1-5alkyl;
m is an integer selected from 0, 1, 2, 3, 4 and 5;
n is 0 or 1;
with the proviso that when n is 0, m is an integer selected from 1, 2, 3, 4 and 5;
R4 is hydrogen, hydroxy, hydroxy-C1-5alkyl, cyano, cyano-C1-5alkyl or C1-5alkyl;
R5 is hydrogen or C1-5alkyl;
R6 is hydrogen, C1-5alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-5alkyl, hydroxy, C1-5alkoxy, C3-8cycloalkyloxy or \u2014N(R11)R12;
R7 and R8 are the same or different, and independently are hydrogen, halogen, C1-5alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-5alkyl, hydroxy, C1-5alkoxy, C3-8cycloalkyloxy, \u2014N(R11a)R12a, \u2014CO2R13, cyano, nitro, C1-5alkylthio, trifluoromethyl or trifluoromethoxy; or R7 and R8 are taken together to form \u2014CH2\u2014CH2\u2014CH2\u2014CH2\u2014 or \u2014CH\u2550CH\u2014CH\u2550CH\u2014;
R10 is hydrogen, C1-5alkyl, halogen, cyano or \u2014CO2R19;
Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C1-5alkyl, C3-8cycloalkyl, C2-5alkenyl, C2-5alkynyl, C1-5alkoxy, C1-5alkylthio, C1-5alkylsulfinyl, C1-5alkylsulfonyl, cyano, nitro, hydroxy, \u2014CO2R19a, \u2014C(\u2550O)R19a, \u2014CONR11bR12b, \u2014OC(\u2550O)R19a, \u2014NR11bCO2R19a, \u2014S(O)rNR11bR12b, hydroxy-C2-5alkylamino-C2-5alkoxy, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy, methylenedioxy, ethylenedioxy and \u2014N(R20)R21; with the proviso that when Y is N, and the cyclic amino group is 5-membered ring, then Ar is aryl or heteroaryl which aryl or heteroaryl is substituted with at least one of substituents which are selected from halogen and trifluoromethyl;
R1 and R12 are the same or different, and independently are hydrogen, C1-5alkyl, C3-8cycloalkyl or C3-8cycloalkyl-C1-5alkyl;
R11a and R12a are the same or different, and independently are hydrogen, C1-5alkyl, C3-8cycloalkyl or C3-8cycloalkyl-C1-5alkyl;
R11b and R12b are the same or different, and independently are hydrogen, C1-5alkyl, C3-8cycloalkyl or C3-8cycloalkyl-C1-5alkyl;
R13 is hydrogen, C1-5alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-5alkyl, C1-5alkoxy-C1-5alkyl, C3-8cycloalkyloxy-C1-5alkyl or phenyl;
R19 is hydrogen or C1-5alkyl;
R19a is hydrogen or C1-5alkyl;
r is 1 or 2;
R20 and R21 are the same or different, and independently are hydrogen or C1-5alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
12. The pyrrolopyrimidine derivative substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is N; the cyclic amino group, m, n, R1, R2, R3, R4, R5, R6, R7, R8 and Ar are as defined in claim 11; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
13. The pyrrolopyrimidine derivative substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is N; m is an integer selected from 1, 2, 3, 4 and 5; n is 0; R1, R2, R4 and R5 are hydrogen; the cyclic amino group, R6, R7, R8 and Ar are as defined in claim 11; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
14. The pyrrolopyrimidine derivative substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is N; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; m is an integer selected from 1, 2 and 3; n is 0; R1, R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or C1-5alkyl; Ar is phenyl or pyridyl which phenyl or pyridyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and \u2014N(R20)R21 (wherein R20 and R21 are the same or different, and independently are hydrogen or C1-3alkyl); with the proviso that when the cyclic amino group is 5-membered ring, Ar is phenyl or pyridyl which phenyl or pyridyl is substituted with at least one of substituents which are selected from halogen and trifluoromethyl; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
15. The pyrrolopyrimidine derivative substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is N; the cyclic amino group is a 6-membered saturated cyclic amine; m is an integer selected from 1, 2 and 3; n is 0; R1, R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or methyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of chloro, bromo, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and dimethylamino; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
16. The pyrrolopyrimidine derivatives substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is N; m is 1; n is 0; R1 is C1-5alkyl or hydroxy-C1-5alkyl; R2, R4 and R5 are hydrogen; the cyclic amino group, R6, R7, R8 and Ar are as defined in claim 11; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
17. The pyrrolopyrimidine derivatives substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is N; m is 1; n is 0; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; R1 is C1-5alkyl or hydroxy-C1-5alkyl; R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or C1-5alkyl; Ar is phenyl or pyridyl which phenyl or pyridyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and \u2014N(R20)R21 (wherein R20 and R21 are the same or different, and independently are hydrogen or C1-3alkyl); individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
18. The pyrrolopyrimidine derivatives substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is N; m is 1; n is 0; the cyclic amino group is a 6-membered saturated cyclic amine; R1 is C1-5alkyl or hydroxy-C1-5alkyl; R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or methyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of chloro, bromo, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and dimethylamino; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
19. The pyrrolopyrimidine derivative substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is N; m is an integer selected from 1, 2, 3, 4 and 5; n is 0; R1, R2 and R5 are hydrogen; R4 is cyano; the cyclic amino group, R6, R7, R8 and Ar are as defined in claim 11, wherein a group represented by \u2014(CR1R2)m\u2014(CHR3)n\u2014OH and R4 are substituted on the same carbon atom of the cyclic amine; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
20. The pyrrolopyrimidine derivative substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is N; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; m is an integer selected from 1, 2 and 3; n is 0; R1, R2 and R5 are hydrogen; R4 is cyano; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or C1-5alkyl; Ar is phenyl or pyridyl which phenyl or pyridyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and \u2014N(R20)R21 (wherein R20 and R21 are the same or different, and independently are hydrogen or C1-3alkyl), wherein a group represented by \u2014(CR1R2)m\u2014(CHR3)n\u2014OH and R4 are substituted on the same carbon atom of the cyclic amine; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
21. The pyrrolopyrimidine derivative substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is N; the cyclic amino group is a 6-membered saturated cyclic amine; m is an integer selected from 1, 2 and 3; n is 0; R1, R2 and R5 are hydrogen; R4 is cyano; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or methyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of chloro, bromo, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and dimethylamino, wherein a group represented by \u2014(CR1R2)m\u2014(CHR3)n\u2014OH and R4 are substituted on the same carbon atom of the cyclic amine; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
22. The pyrrolopyridine derivative substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is CR10; the cyclic amino group, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R10 and Ar are as defined in claim 11; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
23. The pyrrolopyridine derivative substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is CR10; m is an integer selected from 1, 2, 3, 4 and 5; n is 0; R1, R2, R4 and R5 are hydrogen; R10 is hydrogen or halogen; the cyclic amino group, R6, R7, R8 and Ar are as defined in claim 11; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
24. The pyrrolopyridine derivative substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is CR10; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; m is an integer selected from 1, 2 and 3; n is 0; R1, R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or C1-5alkyl; R10 is hydrogen or halogen; Ar is phenyl or pyridyl which phenyl or pyridyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and \u2014N(R20)R21 (wherein R20 and R21 are the same or different, and independently are hydrogen or C1-3alkyl); individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
25. The pyrrolopyridine derivative substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is CR10; the cyclic amino group is a 6-membered saturated cyclic amine; m is an integer selected from 1, 2 and 3; n is 0; R1, R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or methyl; R10 is hydrogen; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of chloro, bromo, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and dimethylamino; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
26. The pyrrolopyridine derivatives substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is CR10; m is 1; n is 0; R1 is C1-5alkyl or hydroxy-C1-5alkyl; R2, R4 and R5 are hydrogen; R10 is hydrogen or halogen; the cyclic amino group, R6, R7, R8 and Ar are as defined in claim 11; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
27. The pyrrolopyridine derivatives substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is CR10; m is 1; n is 0; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; R1 is C1-5alkyl or hydroxy-C1-5alkyl; R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or C1-5alkyl; R10 is hydrogen or halogen; Ar is phenyl or pyridyl which phenyl or pyridyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and \u2014N(R20)R21 (wherein R20 and R21 are the same or different, and independently are hydrogen or C1-3alkyl); individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
28. The pyrrolopyridine derivatives substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is CR10; m is 1; n is 0; the cyclic amino group is a 6-membered saturated cyclic amine; R1 is C1-5alkyl or hydroxy-C1-5alkyl; R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or methyl; R10 is hydrogen; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of chloro, bromo, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and dimethylamino; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
29. The pyrrolopyridine derivative substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is CR10; m is an integer selected from 1, 2, 3, 4 and 5; n is 0; R1, R2 and R5 are hydrogen; R4 is cyano; R10 is hydrogen or halogen; the cyclic amino group, R6, R7, R8 and Ar are as defined in claim 11, wherein a group represented by \u2014(CR1R2)m\u2014(CHR3)\u2014OH and R4 are substituted on the same carbon atom of the cyclic amine; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
30. The pyrrolopyridine derivative substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is CR10; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; m is an integer selected from 1, 2 and 3; n is 0; R1, R2 and R5 are hydrogen; R4 is cyano; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or C1-5alkyl; R10 is hydrogen or halogen; Ar is phenyl or pyridyl which phenyl or pyridyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and \u2014N(R20)R21 (wherein R20 and R21 are the same or different, and independently are hydrogen or C1-3alkyl), wherein a group represented by \u2014(CR1R2)m\u2014(CHR3)n\u2014OH and R4 are substituted on the same carbon atom of the cyclic amine; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
31. The pyrrolopyridine derivative substituted with the cyclic amino group according to claim 11 represented by formula V, wherein Y is CR10; the cyclic amino group is a 6-membered saturated cyclic amine; m is an integer selected from 1, 2 and 3; n is 0; R1, R2 and R5 are hydrogen; R4 is cyano; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or methyl; R10 is hydrogen; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of chloro, bromo, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and dimethylamino, wherein a group represented by \u2014(CR1R2)m\u2014(CHR3)n\u2014OH and R4 are substituted on the same carbon atom of the cyclic amine; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
32. The pyrrolopyrimidine or pyrrolopyridine derivative substituted with the cyclic amino group according to claim 1, which is a compound represented by the following formula VII:
(wherein the cyclic amino group is represented by the following formula VIII:
in which the cyclic amino group is a 3- to 8-membered saturated cyclic amine or a 3- to 8-membered saturated cyclic amine bridged with C1-5alkylene or C1-4alkylene-O-C1-4alkylene between any different two carbon atoms of the cyclic amine, which cyclic amine is substituted with a group represented by \u2014(CR1R2)m\u2014(CHR3)n\u2014OR9, R4 and R5 independently on the same or different carbon atoms of the cyclic amine;
Y is N or CR10;
R1 is hydrogen, hydroxy, C1-5alkyl, C1-5alkoxy-C1-5alkyl or hydroxy-C1-5alkyl;
R2 is hydrogen or C1-5alkyl;
R3 is hydrogen, cyano, C1-5alkyl, C1-5alkoxy-C1-5alkyl or hydroxy-C1-5alkyl;
m is an integer selected from 0, 1, 2, 3, 4 and 5;
n is 0 or 1;
with the proviso that when n is 0, m is an integer selected from 1, 2, 3, 4 and 5;
R4 is hydrogen, hydroxy, hydroxy-C1-5alkyl, cyano, cyano-C1-5alkyl or C1-5alkyl;
R5 is hydrogen or C1-5alkyl;
R6 is hydrogen, C1-5alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-5alkyl, hydroxy, C1-5alkoxy, C3-8cycloalkyloxy or \u2014N(R11)R21;
R7 and R8 are the same or different, and independently are hydrogen, halogen, C1-5alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-5alkyl, hydroxy, C1-5alkoxy, C3-8cycloalkyloxy, \u2014N(R11a)R12a, \u2014CO2R13, cyano, nitro, C1-5alkylthio, trifluoromethyl or trifluoromethoxy; or R7 and R8 are taken together to form \u2014CH2\u2014CH2\u2014CH2\u2014CH2\u2014 or \u2014CH\u2550CH\u2014CH\u2550CH\u2014;
R9 is C1-24acyl, C1-10alkoxycarbonyl, aryl-C1-5alkyloxycarbonyl, \u2014CO\u2014O\u2014CHR14\u2014O\u2014CO\u2014R15, \u2014P(\u2550O)(OR14a)OR15a, \u2014CO\u2014(CH2)p\u2014(CHR16)q\u2014NR17R18, arylcarbonyl or heteroarylcarbonyl, wherein each said acyl, aryl and heteroaryl is unsubstituted or substituted with C1-5alkoxy, and C1-24acyl optionally includes one to six double bonds;
R10 is hydrogen, C1-5alkyl, halogen, cyano or \u2014CO2R19;
Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C1-5alkyl, C3-8cycloalkyl, C2-5alkenyl, C2-5alkynyl, C1-5alkoxy, C1-5alkylthio, C1-5alkylsulfinyl, C1-5alkylsulfonyl, cyano, nitro, hydroxy, \u2014C2R19a, \u2014C(\u2550O)R19a, \u2014CONR11bR12b, \u2014OC(\u2550O)R19a, \u2014NR11bCO2R19a, \u2014S(O)rNR11bR12b, hydroxy-C2-5alkylamino-C2-5alkoxy, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy, methylenedioxy, ethylenedioxy and \u2014N(R20)R21;
R11 and R12 are the same or different, and independently are hydrogen, C1-5alkyl, C3-8cycloalkyl or C3-8cycloalkyl-C1-5alkyl;
R11a and R12a are the same or different, and independently are hydrogen, C1-5alkyl, C3-8cycloalkyl or C3-8cycloalkyl-C1-5alkyl;
R11b and R12b are the same or different, and independently are hydrogen, C1-5alkyl, C3-8cycloalkyl or C3-8cycloalkyl-C1-5alkyl;
R13 is hydrogen, C1-5alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-5alkyl, C1-5alkoxy-C1-5alkyl, C3-8cycloalkyloxy-C1-5alkyl or phenyl;
R14 and R15 are the same or different, and independently are hydrogen, C1-5alkyl or aryl-C1-5alkyl;
R14a and R15a are the same or different, and independently are hydrogen, C1-5alkyl or aryl-C1-5alkyl;
R16 is hydrogen, C1-5alkyl, aryl, heteroaryl, aryl-C1-5alkyl, heteroaryl-C1-5alkyl, hydroxy-C1-5alkyl, hydroxycarbonyl-C1-5alkyl, hydroxyphenyl-C1-5alkyl, C1-5alkoxy-C1-5alkyl, amino-C1-5alkyl, guanidino-C1-5alkyl, mercapto-C1-5alkyl, C1-5alkylthio-C1-5alkyl or aminocarbonyl-C1-5alkyl;
R17 and R18 are the same or different, and independently are hydrogen, C1-5alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-5alkyl, C1-10acyl, C1-10alkoxycarbonyl and aryl-C1-5alkyloxycarbonyl,
or R16 and R17 are taken together to form \u2014CH2\u2014, \u2014CH2CH2\u2014, \u2014CH2CH2CH2\u2014 or \u2014CH2CH2CH2CH2\u2014;
p is an integer selected from 0, 1, 2, 3, 4 and 5;
q is 0 or 1;
R19 is hydrogen or C1-5alkyl;
R19a is hydrogen or C1-5alkyl;
r is 1 or 2;
R20 and R21 are the same or different, and independently are hydrogen or C1-5alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
33. The pyrrolopyrimidine derivative substituted with the cyclic amino group according to claim 32 represented by the formula VII, wherein Y is N; the cyclic amino group, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9 and Ar are as defined in claim 32; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
34. The pyrrolopyrimidine derivative substituted with the cyclic amino group according to claim 32 represented by formula VII, wherein Y is N; m is an integer selected from 1, 2, 3, 4 and 5; n is O; R1, R2, R4 and R5 are hydrogen; the cyclic amino group, R6, R7, R8, R9 and Ar are as defined in claim 32; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
35. The pyrrolopyrimidine derivative substituted with the cyclic amino group according to claim 32 represented by the formula VII, wherein the cyclic amino group is a 4- to 7-membered saturated cyclic amine; m is an integer selected from 1, 2, 3, 4 and 5; n is 0; Y is N; R1, R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or C1-5alkyl; Ar is phenyl or pyridyl which phenyl or pyridyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and \u2014N(R20)R21 (wherein R20 and R21 are the same or different, and independently are hydrogen or C1-3alkyl); R9 is as defined in claim 32; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
36. The pyrrolopyrimidine derivative substituted with the cyclic amino group according to claim 32 represented by the formula VII, wherein the cyclic amino group is a 6-membered saturated cyclic amine; m is an integer selected from 1, 2 and 3; n is 0; Y is N; R1, R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or methyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of chloro, bromo, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and dimethylamino; R9 is as defined in claim 32; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
37. The pyrrolopyridine derivative substituted with the cyclic amino group according to claim 32 represented by formula VII, wherein Y is CR10; the cyclic amino group, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and Ar are as defined in claim 32; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
38. The pyrrolopyridine derivative substituted with the cyclic amino group according to claim 32 represented by formula VII, wherein Y is CR10; m is an integer selected from 1, 2, 3, 4 and 5; n is 0; R1, R2, R4 and R5 are hydrogen; the cyclic amino group, R6, R7, R8, R9, R10 and Ar are as defined in claim 32; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
39. The pyrrolopyridine derivative substituted with the cyclic amino group according to claim 32 represented by formula VII, wherein Y is CR10; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; m is an integer selected from 1, 2 and 3; n is 0; R1, R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or C1-5alkyl; R10 is hydrogen or halogen; Ar is phenyl or pyridyl which phenyl or pyridyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and \u2014N(R20)R21 (wherein R20 and R21 are the same or different, and independently are hydrogen or C1-3alkyl); R9 is as defined in claim 32; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
40. The pyrrolopyridine derivative substituted with the cyclic amino group according to claim 32 represented by formula VII, wherein Y is CR10; the cyclic amino group is a 6-membered saturated cyclic amine; m is an integer selected from 1, 2 and 3; n is 0; R1, R2, R4 and R5 are hydrogen; R6 is methyl; R7 and R8 are the same or different, and independently are hydrogen or methyl; R10 is hydrogen; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of chloro, bromo, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and dimethylamino; R9 is as defined in claim 32; individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
41. Compounds represented by formula I according to claim 1, which compounds are selected from the group consisting of
2-{1-7-(2,6-dibromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-2-yl}-ethanol,
2-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-2-yl}-ethanol,
2-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-2-yl}-ethanol,
2-{1-7-(4-bromo-2,6-diethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-2-yl}-ethanol,
2-{1-2,5-dimethyl-7-(2,4,6-tribromo-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-2-yl}-ethanol,
3-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-2-yl}-propan-1-ol,
3-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-2-yl}-propan-1-ol,
{1-7-(2,4-dibromo-6-methoxy-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-3-yl}-methanol,
{1-7-(2,4-dibromo-6-methylsulfanyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-3-yl}-methanol,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-3-yl}-methanol,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-3-yl}-methanol,
{1-2,5-dimethyl-7-(2,4,6-tribromo-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-3-yl}-methanol,
2-{1-7-(2,6-dibromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-3-yl}-ethanol,
2-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-3-yl}-ethanol,
2-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-3-yl}-ethanol,
2-{1-2,5-dimethyl-7-(2,4,6-tribromo-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-3-yl}-ethanol,
{1-2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-7-(2,6-dibromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-2-methyl-9-(2,4,6-trimethyl-phenyl)-9H-1,3,9-triaza-fluoren-4-yl-piperidin-4yl}-methanol,
{1-7-(4-bromo-2,6-diethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-7-(4-bromo-2,6-diethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-2,5,6-trimethyl-7-(2,4,6-tribromo-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-2,5-dimethyl-7-(2,4,6-tribromo-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-7-(4-bromo-2,6-dichloro-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-7-(4-bromo-2,6-dichloro-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-7-(2,6-dibromo-4-isopropyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-7-(2,6-dibromo-4-isopropyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-7-(4-chloro-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-7-(4-chloro-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
2-{1-7-(2,6-dibromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-ethanol,
2-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-ethanol,
2-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-ethanol,
2-{1-2,5,6-trimethyl-7-(2,4,6-tribromo-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-ethanol,
2-{1-2,5-dimethyl-7-(2,4,6-tribromo-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-ethanol,
3-{1-2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-7-(2,6-dibromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-2,5-dimethyl-7-(2,4,6-tribromo-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-7-(4-bromo-2,6-dichloro-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-7-(4-bromo-2,6-dichloro-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-propan-1-ol,
{1-7-(2,6-dibromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-3-methyl-piperidin-3-yl}-methanol,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-3-methyl-piperidin-3-yl}-methanol,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-3-methyl-piperidin-3-yl}-methanol,
1-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-ethane-1,2-diol,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-pyrrolidin-2-yl}-methanol,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-pyrrolidin-2-yl}-methanol,
2-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-pyrrolidin-3-yl}-ethanol,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-azepan-4-yl}-methanol,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-azepan-4-yl}-methanol,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-2-yl}-acetonitrile,
1-2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidine-3-carbonitrile,
1-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidine-3-carbonitrile,
1-7-(2,4-dibromo-6-methylsulfanyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidine-3-carbonitrile,
1-7-(2,6-dibromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidine-3-carbonitrile,
1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidine-3-carbonitrile,
1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidine-3-carbonitrile,
1-7-(4-isopropyl-2-methylsulfanyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidine-3-carbonitrile,
1-7-(4-isopropyl-2-methylsulfanyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidine-3-carbonitrile,
1-7-(2-bromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidine-3-carbonitrile,
1-7-(4-bromo-2,6-diethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidine-3-carbonitrile,
1-7-(4-bromo-2,6-diethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidine-3-carbonitrile,
{1-7-(2,6-dibromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-3-yl}-acetonitrile,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-3-yl}-acetonitrile,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-3-yl}-acetonitrile,
3-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-3-yl}-propionitrile,
3-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-3-yl}-propionitrile,
1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidine-4-carbonitrile,
1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidine-4-carbonitrile,
{1-2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-7-(2,6-dibromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-7-(4-bromo-2,6-diethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-7-(4-bromo-2,6-diethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-2,5,6-trimethyl-7-(2,4,6-tribromo-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-2,5-dimethyl-7-(2,4,6-tribromo-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-7-(4-bromo-2,6-dichloro-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-7-(4-bromo-2,6-dichloro-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-7-(2,6-dibromo-4-isopropyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-7-(2,6-dibromo-4-isopropyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-7-(4-methoxy-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-7-(4-methoxy-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-7-(4-chloro-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-7-(4-chloro-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
8-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-8-aza-bicyclo3.2.1octane-3-carbonitrile,
8-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-8-aza-bicyclo3.2.1octane-3-carbonitrile,
1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-pyrrolidine-3-carbonitrile,
1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-pyrrolidine-3-carbonitrile,
1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-azepane-4-carbonitrile,
1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-azepane-4-carbonitrile,
1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-3-hydroxymethyl-piperidine-3-carbonitrile,
{1-7-(4-isopropyl-2-methylsulfanyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-7-(2-bromo-4-isopropyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-7-(2,4-dibromo-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-7-(2,6-dibromo-4-chloro-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
2-{1-7-(2,6-dibromo-4-chloro-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-ethanol,
1-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-propane-1,3-diol,
{1-7-(2,6-dibromo-4-chloro-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-pyrrolidin-3-yl}-acetonitrile,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-pyrrolidin-3-yl}-acetonitrile,
{1-2,5-dimethyl-7-(2,4,6-trichloro-phenyl)-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
{1-7-(2,6-dichloro-4-trifluoromethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-methanol,
3-{1-7-(4-chloro-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-propan-1-ol,
1-7-(4-chloro-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidine-4-carbonitrile,
{1-7-(2,6-Dichloro-4-trifluoromethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-acetonitrile,
1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-azetidine-3-carbonitrile,
1-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-ethanol,
1-{1-7-(4-isopropyl-2-methylsulfanyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-ethanol,
1-{1-7-(4-chloro-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-ethanol,
1-{1-7-(4-chloro-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-ethanol,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-3-methyl-piperidin-4-yl}-methanol,
{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-3-methyl-piperidin-4-yl}-methanol,
{8-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-8-aza-bicyclo3.2.1oct-3-yl}-methanol,
{8-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-8-aza-bicyclo3.2.1oct-3-yl}-methanol,
{8-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-8-aza-bicyclo3.2.1oct-3-yl}-acetonitrile,
{8-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-8-aza-bicyclo3.2.1oct-3-yl}-acetonitrile,
2-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-malononitrile,
2-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-yl}-malononitrile,
2-{1-1-(2,4-dichloro-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-3-yl}-ethanol,
2-{1-1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-3-yl}-ethanol,
{1-1-(2,4-dichloro-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
2-{1-1-(2,4-dichloro-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
3-{1-1-(2,4-dichloro-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
1-1-(2,4-dichloro -phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-3-carbonitrile,
1-1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-3-carbonitrile,
{1-1-(2,4-dichloro -phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-3-yl}-acetonitrile, 1-1-(2,4-dichloro -phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
{1-1-(2,4-dichloro -phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
2-{1-1-(4-bromo-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-3-yl}-ethanol,
{1-1-(4-bromo-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-1-(4-chloro-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-1-(4-chloro-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
2-{1-1-(4-bromo-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-1-(4-chloro-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-1-(4-chloro-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
3-{1-1-(4-bromo-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-1-(4-chloro-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-1-(4-chloro-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
1-1-(4-bromo-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-3-carbonitrile,
1-1-(4-bromo-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-1-(4-chloro-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-1-(4-chloro-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
{1-1-(4-bromo-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-1-(4-chloro-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-1-(2,6-dibromo-4-isopropyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-1-(2,6-dibromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-2,3,6-trimethyl-1-(2,4,6-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-3,6-dimethyl-1-(2,4,6-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-1-(4-bromo-2,6-dichloro-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-1-(4-bromo-2,6-dichloro-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-2,3,6-trimethyl-1-(2,4,6-trichloro-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-3,6-dimethyl-1-(2,4,6-trichloro-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-1-(2,6-dibromo-4-chloro-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-1-(2,6-dibromo-4-chloro-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-1-(4-methoxy-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-1-(4-methoxy-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-1-(2-bromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-1-(4-isopropyl-2-methylsulfanyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-1-(2,4-dibromo-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-1-(2-bromo-4-trifluoromethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-2,3,6-trimethyl-1-(2,4,5-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
{1-3,6-dimethyl-1-(2,4,5-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-methanol,
2-{1-1-(2,6-dibromo-4-isopropyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-1-(2,6-dibromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-2,3,6-trimethyl-1-(2,4,6-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-3,6-dimethyl-1-(2,4,6-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-1-(4-bromo-2,6-dichloro-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-1-(4-bromo-2,6-dichloro-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-2,3,6-trimethyl-1-(2,4,6-trichloro-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-3,6-dimethyl-1-(2,4,6-trichloro-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-1-(2,6-dibromo-4-chloro-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-1-(2,6-dibromo-4-chloro-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-1-(4-methoxy-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-1-(4-methoxy-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4yl-piperidin-4-yl}-ethanol,
2-{1-1-(2-bromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4yl-piperidin-4-yl}-ethanol,
2-{1-1-(4-isopropyl-2-methylsulfanyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-1-(2,4-dibromo-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-2,3,6-trimethyl-1-(2,4,5-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-3,6-dimethyl-1-(2,4,5-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
2-{1-5-bromo-1-(4-chloro-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethanol,
3-{1-1-(2,6-dibromo-4-isopropyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-1-(2,6-dibromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-2,3,6-trimethyl-1-(2,4,6-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-3,6-dimethyl-1-(2,4,6-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-1-(4-bromo-2,6-dichloro -phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-1-(4-bromo-2,6-dichloro -phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4yl-piperidin-4-yl}-propan-1-ol,
3-{1-2,3,6-trimethyl-1-(2,4,6-trichloro-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-3,6-dimethyl-1-(2,4,6-trichloro -phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-1-(2,6-dibromo-4-chloro-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-1-(2,6-dibromo-4-chloro-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-1-(4-methoxy-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-1-(4-methoxy-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-1-(4-isopropyl-2-methylsulfanyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-2,3,6-trimethyl-1-(2,4,5-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
3-{1-3,6-dimethyl-1-(2,4,5-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propan-1-ol,
1-{1-1-(4-bromo-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethane-1,2-diol,
1-{1-1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-ethane-1,2-diol,
1-{1-1-(4-bromo-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propane-1,3-diol,
1-{1-1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-propane-1,3-diol,
1-1-(2,6-dibromo-4-isopropyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-1-(2,6-dibromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-2,3,6-trimethyl-1-(2,4,6-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-3,6-dimethyl-1-(2,4,6-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-1-(4-bromo-2,6-dichloro-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-1-(4-bromo-2,6-dichloro-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-2,3,6-trimethyl-1-(2,4,6-trichloro-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-3,6-dimethyl-1-(2,4,6-trichloro-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-1-(2,6-dibromo-4-chloro-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-1-(2,6-dibromo-4-chloro-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-1-(4-methoxy-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-1-(4-methoxy-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-1-(2-bromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-1-(4-isopropyl-2-methylsulfanyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-1-(2,4-dibromo-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-1-(2-bromo-4-trifluoromethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-2,3,6-trimethyl-1-(2,4,5-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
1-3,6-dimethyl-1-(2,4,5-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidine-4-carbonitrile,
{1-1-(4-chloro-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-1-(2,6-dibromo-4-isopropyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-1-(2,6-dibromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-2,3,6-trimethyl-1-(2,4,6-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-3,6-dimethyl-1-(2,4,6-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-1-(4-bromo-2,6-dichloro -phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-1-(4-bromo-2,6-dichloro -phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-2,3,6-trimethyl-1-(2,4,6-trichloro -phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-3,6-dimethyl-1-(2,4,6-trichloro -phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-1-(2,6-dibromo-4-chloro -phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-1-(2,6-dibromo-4-chloro -phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-1-(4-methoxy-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-1-(4-methoxy-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-1-(2-bromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-1-(4-isopropyl-2-methylsulfanyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-1-(2,4-dibromo-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-1-(2-bromo-4-trifluoromethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
{1-3,6-dimethyl-1-(2,4,5-tribromo-phenyl)-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-yl}-acetonitrile,
carbonic acid 1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-ylmethyl ester ethyl ester,
pyridine-2-carboxylic acid 1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-ylmethyl ester,
methoxy-acetic acid 1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-ylmethyl ester,
methoxy-acetic acid 1-1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo2,3-bpyridin-4-yl-piperidin-4-ylmethyl ester,
carbonic acid benzyl ester 1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-ylmethyl ester,
decanoic acid 1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-ylmethyl ester,
3-diethylamino-propionic acid 1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-ylmethyl ester
and phosphoric acid mono-{1-7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo2,3-dpyrimidin-4-yl-piperidin-4-ylmethyl}ester,
individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
42. An antagonist for CRF receptors, comprising a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group, a pharmaceutically acceptable salt thereof or its hydrate according to any one of claims 1 to 41, as an active ingredient.
43. Use of a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group, a pharmaceutically acceptable salt thereof or its hydrate according to any one of claim 1 to 41, for the manufacture of an antagonist for CRF receptors.